SMTL ID : 6n3o.1

Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.40 Å

Oligo State

monomer

Ligands

1 x KA7: N-{3-[(2-aminopyrimidin-5-yl)ethynyl]-2,4-difluorophenyl}-5-chloro-2-methoxypyridine-3-sulfonamide(Non-covalent)

KA7.1: 20 residues within 4Å: Chain A: L.23, V.31, A.44, V.45, K.46, V.64, L.67, I.75, V.76, Y.78, I.104, M.106, E.107, Y.108, C.109, F.159, G.169, D.170, F.171, L.173 12 PLIP interactions: 12 interactions with chain A Hydrophobic interactions: A:A.44, A:K.46, A:L.67, A:I.104, A:F.159 Hydrogen bonds: A:C.109, A:C.109, A:D.170, A:F.171 Water bridges: A:G.172, A:L.173 pi-Cation interactions: A:K.46

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Fujimoto, J. et al., Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode. Acs Med.Chem.Lett. (2019)

Release Date

2019-10-09

Peptides

eIF-2-alpha kinase GCN2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

eIF-2-alpha kinase GCN2

Related Entries With Identical Sequence